News

The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market.

Roche chief medical officer and global product development head Sandra Horning said: “Today’s approval is an important advance for women newly diagnosed with this type of ovarian cancer.

The Boston-based clinical-stage biotechnology company had been conducting the mid-stage trials for the oral disintegrating tablet formulation in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT). Flex Pharma said

PFIC is a rare and life-threatening liver disease with no approved pharmacologic treatment option. A4250 is an ileal bile acid transporter (IBAT) inhibitor, which is being developed for

These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. Neridronate, a bisphosphonate, is an innovative investigational medicine discovered

Ganovo is the first Direct-acting Anti-viral Agent (DAA) developed by a domestic company in China and has been selected as a National Science and Technology Major Project for

The approval has been given for treatment of patients whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. Merck said that the

An independent data monitoring committee (IDMC) has recommended the partnership to stop the trials of lanabecestat, as it is unlikely to meet primary endpoints. AstraZeneca IMED biotech unit

In addition, BridgeBio announced that it was launching a new subsidiary, Origin Biosciences, with sufficient capital to support clinical development of ALXN1101 through potential regulatory approval and commercialization.